Key Points
- Director Marc Duey bought 21,459 shares on Dec. 10 at an average price of $1.17 (total ~$25,107), raising his stake 9.14% to 256,155 shares valued at about $299,701.
- Aprea stock traded at $0.96 on Friday (+1.9%) with a market cap of ~$6.08 million and a 12‑month range of $0.90–$5.00, while volume was below average (22,430 vs. 52,004).
- The company reported a ($0.47) EPS miss with no revenue and very negative profitability metrics (negative ROE and net margin), and analysts are mixed—two Buys, one Sell—with an average target of $15.50 and Weiss Ratings reiterating a sell (e+) rating.
Aprea Therapeutics, Inc. (NASDAQ:APRE - Get Free Report) Director Marc Duey bought 21,459 shares of the stock in a transaction that occurred on Wednesday, December 10th. The shares were purchased at an average cost of $1.17 per share, with a total value of $25,107.03. Following the purchase, the director directly owned 256,155 shares of the company's stock, valued at $299,701.35. The trade was a 9.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.
Aprea Therapeutics Stock Up 1.9%
APRE traded up $0.02 during trading on Friday, reaching $0.96. 22,430 shares of the stock traded hands, compared to its average volume of 52,004. The stock's 50-day moving average is $1.30 and its 200 day moving average is $1.54. Aprea Therapeutics, Inc. has a 12 month low of $0.90 and a 12 month high of $5.00. The stock has a market capitalization of $6.08 million, a PE ratio of -0.45 and a beta of 1.23.
Aprea Therapeutics (NASDAQ:APRE - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.36). The business had revenue of $0.00 million during the quarter. Aprea Therapeutics had a negative return on equity of 88.12% and a negative net margin of 2,666.46%. As a group, equities research analysts anticipate that Aprea Therapeutics, Inc. will post -2.55 EPS for the current year.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Aprea Therapeutics in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $15.50.
Read Our Latest Research Report on Aprea Therapeutics
Aprea Therapeutics Company Profile
(
Get Free Report)
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
